PhaseBio Pharmaceuticals Operating Income

Operating Income of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending June 29, 2021 was $-21.1 Million (a -17.91% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 2.74%
  • Annual Operating Income for 2020 was $-84.9 Million (a 113.55% increase from previous year)
  • Annual Operating Income for 2019 was $-39.7 Million (a 102.28% increase from previous year)
  • Annual Operating Income for 2018 was $-19.6 Million (a 130.08% increase from previous year)
  • Twelve month Operating Income ending June 29, 2021 was $-93.2 Million (a -3.16% decrease compared to previous quarter)
  • Twelve month trailing Operating Income increased by 32.8% year-over-year
Trailing Operating Income for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-93.2 Million $-96.2 Million $-84.9 Million $-70.2 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of PhaseBio Pharmaceuticals

Most recent Operating Incomeof PHAS including historical data for past 10 years.

Interactive Chart of Operating Income of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-21.05 $-25.65
2020 $-25.98 $-20.49 $-24.1 $-14.29 $-84.86
2019 $-11.28 $-11.59 $-9.48 $-7.38 $-39.74
2018 $-7.66 $-5.0 $-4.11 $-2.88 $-19.64
2017 $-1.9 $-8.54

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.